


| | | |
|--|---|---|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTORNEY'S DOCKET NUMBER HORIUCHI 4 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | |
| INTERNATIONAL APPLICATION NO. PCT/JP00/03017 | INTERNATIONAL FILING DATE 11 May 2000 | U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/743704 |
| TITLE OF INVENTION HAIR GROWTH STIMULANTS | | |
| APPLICANT(S) FOR DO/EO/US Isao HORIUCHI | | |
| <p style="text-align: center;">TUESDAY - (MONDAY WAS A HOLIDAY) S 2</p> <p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 00/69399). <input checked="" type="checkbox"/> Formal drawings, 1 sheets, Figures 1-1. <input checked="" type="checkbox"/> Courtesy Copy of the International Search Report. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|-------------------------------|-----------------------|----------------------------------|--------------|--------------|------|--------------|--------|--|-----------|--------------------|-------|--|-----------|---|--|--|-----------|--------------------------------------|--|--|-----------|--------------------------------------|--------------|--------------|------|--------------|------|--|-----------|--------------------|-----|--|-----------|--------------------------------------|--|--|-----------|---|--|--|-----------|-------------------|--|--|-----------|---|--|--|----|-----------------------------|--|--|-----------|---|--|--|----|------------------------------|--|--|-----------|--|--|--|---------------------------|----|--|--|--|---------|----|--|
| U.S. APPLICATION NO. (If known, see 37 CFR 1.5) | International Application No. | Attorney's Docket No. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 09/743704 | | PCT/JPOO/03017 | HORIUCHI 4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>17. [xx] The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00</p> | | | CALCULATIONS PTO USE ONLY | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | | \$ 860.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%;"> <tr> <td>Claims as Originally Presented</td> <td>Number Filed</td> <td>Number Extra</td> <td>Rate</td> </tr> <tr> <td>Total Claims</td> <td>6 - 20</td> <td></td> <td>X \$18.00</td> </tr> <tr> <td>Independent Claims</td> <td>1 - 3</td> <td></td> <td>X \$80.00</td> </tr> <tr> <td>Multiple Dependent Claims (if applicable)</td> <td></td> <td></td> <td>+\$270.00</td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 860.00</td> </tr> <tr> <td>Claims After Post Filing Prel. Amend</td> <td>Number Filed</td> <td>Number Extra</td> <td>Rate</td> </tr> <tr> <td>Total Claims</td> <td>- 20</td> <td></td> <td>X \$18.00</td> </tr> <tr> <td>Independent Claims</td> <td>- 3</td> <td></td> <td>X \$78.00</td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 860.00</td> </tr> <tr> <td colspan="3"> <p>Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.</p> </td> <td>\$ 430.00</td> </tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL =</td> <td>\$ 430.00</td> </tr> <tr> <td colspan="3"> <p>Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> </td> <td>\$</td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td>\$ 430.00</td> </tr> <tr> <td colspan="3"> <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p> </td> <td>\$</td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td>\$ 430.00</td> </tr> <tr> <td colspan="3"></td> <td style="text-align: center;">Amount to be: refunded</td> <td style="text-align: center;">\$</td> </tr> <tr> <td colspan="3"></td> <td style="text-align: center;">charged</td> <td style="text-align: center;">\$</td> </tr> </table> | | | Claims as Originally Presented | Number Filed | Number Extra | Rate | Total Claims | 6 - 20 | | X \$18.00 | Independent Claims | 1 - 3 | | X \$80.00 | Multiple Dependent Claims (if applicable) | | | +\$270.00 | TOTAL OF ABOVE CALCULATIONS = | | | \$ 860.00 | Claims After Post Filing Prel. Amend | Number Filed | Number Extra | Rate | Total Claims | - 20 | | X \$18.00 | Independent Claims | - 3 | | X \$78.00 | TOTAL OF ABOVE CALCULATIONS = | | | \$ 860.00 | <p>Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.</p> | | | \$ 430.00 | SUBTOTAL = | | | \$ 430.00 | <p>Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> | | | \$ | TOTAL NATIONAL FEE = | | | \$ 430.00 | <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p> | | | \$ | TOTAL FEES ENCLOSED = | | | \$ 430.00 | | | | Amount to be: refunded | \$ | | | | charged | \$ | |
| Claims as Originally Presented | Number Filed | Number Extra | Rate | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total Claims | 6 - 20 | | X \$18.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Independent Claims | 1 - 3 | | X \$80.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Multiple Dependent Claims (if applicable) | | | +\$270.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TOTAL OF ABOVE CALCULATIONS = | | | \$ 860.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Claims After Post Filing Prel. Amend | Number Filed | Number Extra | Rate | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total Claims | - 20 | | X \$18.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Independent Claims | - 3 | | X \$78.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TOTAL OF ABOVE CALCULATIONS = | | | \$ 860.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.</p> | | | \$ 430.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| SUBTOTAL = | | | \$ 430.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> | | | \$ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TOTAL NATIONAL FEE = | | | \$ 430.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p> | | | \$ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TOTAL FEES ENCLOSED = | | | \$ 430.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Amount to be: refunded | \$ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | charged | \$ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>a. [] A check in the amount of \$_____ to cover the above fees is enclosed.</p> <p>b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 430.00, is attached.</p> <p>c. [] Please charge my Deposit Account No. 02-4035 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>d. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>SEND ALL CORRESPONDENCE TO:</p> <p>BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, N.W., SUITE 300 WASHINGTON, D.C. 20001 TEL: (202) 628-5197 FAX: (202) 737-3528 Date of this submission: January 16, 2001</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  SIGNATURE Sheridan Neimark NAME 20,520 REGISTRATION NUMBER | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

SPECIFICATION

HAIR GROWTH TONIC

5 TECHNICAL FIELD

The present invention relates to a hair growth tonic. More specifically, it relates to a growth tonic for hair, which contains the filtrate of lactic acid bacterial cultures as its active ingredient.

10

BACKGROUND ART

A hair consists of a hair shaft that sticks out from the skin surface and a hair root that is inside the skin. The hair root is encapsulated in a hair follicle. The hair root further contains the hair bulb and a hair papilla. The hair papilla has capillaries and nerves, and regulates the formation and growth of the hair through uptake of nutrients from food and oxygen. At a location close to the hair papilla, there are hair matrix cells that generate the hair. In other words, the hair matrix cells take in nutrients and oxygen from the capillaries that enter the hair papilla and hair is formed by repeated division of the cells.

Each hair has an independent lifecycle. Hairs, as a whole, repeat the cycle of growth, falling off, and generation of new hair. In fact, the hair follicle has a hair cycle of growth

phase (anagen), regressive phase (catagen) and a resting phase (telogen). Hair is produced during the growth phase only. During this period, the hair papilla is large, the hair matrix cells work actively to extend the hair, and the hair bulb extends 5 up to the subcutaneous tissue. Once the growth stops, the hair follicle passes through a regressive phase. The first symptom of the regressive phase is the stoppage of melanin production by the hair bulb. After then, most of the other cells of the hair follicle are consumed by the surrounding micropahges to 10 shrink. The hair root shrinks up to a position below the arrector pili muscle and the cells enter to the resting phase. Generally, the growth phase of a hair is 5-6 years, the regressive phase thereof is 2-3 weeks and the resting phase thereof is 2-3 months.

15 When there is some abnormality during the hair cycle, it falls off and baldness starts. The causes of baldness are not fully understood. The lowering of hair follicle function under the influence of the male hormone, the lowering of the metabolic functions of the hair follicle and bulb, the lowering of the 20 physiological functions of the scalp, some localized problem in blood flow due to tension on the scalp, malnutrition, stress, side effects of drugs, heredity, etc could be the reason. Various types of hair growth tonics have been used for preventing and treating baldness. Such hair growth tonics are 25 mostly mixtures of various chemicals that have some effect of

counteracting at least some of the causes listed above. The main component of most of these tonics is a chemical that either has an activating effect on the hair matrix cells or a blood circulation enhancing effect. Most of these tonics are 5 designed to give a hair growth promoting effect (hair nourishment and hair regeneration) by supplying nutrients through the activation of the hair follicles that show diminished hair growth and through enhanced blood flow.

Hair and baldness have been discussed, for instance, in 10 *Shin Keshohin Gaku* (New Cosmetology) compiled by Takeo Mitsui and published by Nanzando (1994), which may be referred.

Patent applications on various hair tonics and hair growth tonics have been applied for. Some examples are disclosed in Japanese Patent Laid-open Publication No. Sho. 15 63-303915 (A hair tonic containing skimmia extract), Japanese Patent Publication No. Hei. 4-5002 (A cosmetic hair tonic containing lipase), Japanese Patent Laid-open Publication No. Hei. 1-254614 (A hair tonic containing fermented herbal stimulant and water-soluble chitosan).

20 As mentioned above, various types of hair tonics and hair growth tonics have been developed. However very few of them are truly effective in suppressing hair loss or promoting hair nourishment and hair growth. Under this situation, it would be very significant to discover a hair growth tonic that is truly 25 effective, because it would be of immense benefit for people

suffering from baldness.

After extensive research undertaken to overcome the above-mentioned problems, the present inventors found that the filtrate of cultures of some microorganisms, lactic acid bacteria in particular, is effective in the treatment of baldness, and completes the present invention.

Thus, an object of the present invention is to provide a hair growth tonic that can effectively promote hair growth, hair nourishment and hair regeneration (hereinafter referred 10 to simply as "hair growth").

DISCLOSURE OF THE INVENTION

A hair growth tonic according to the present invention is characterized by containing filtrate of lactic acid 15 bacterial cultures, as its active ingredient.

Moreover, a hair growth tonic according to another aspect of the present invention is characterized in that the above-mentioned lactic acid bacterium is a bacterium belonging to *Streptococcus* or *Lactobacillus*.

20 In addition, a hair growth tonic according to another aspect of the present invention is characterized in that the above-mentioned lactic acid bacterium of *Streptococcus* is *Streptococcus lactis*.

25 A hair growth tonic according to still another aspect of the present invention is characterized in that the

above-mentioned lactic acid bacterium of *Lactobacillus* is *Lactobacillus bulgaricus*.

Furthermore, a hair growth tonic according to another aspect of the present invention is characterized by containing 5 other known hair growth promoting component in addition to the filtrate of the above-mentioned lactic acid bacterial cultures.

Still further, a hair growth tonic according to another aspect of the present invention is characterized in that the above-mentioned known other growth promoting component is 10 laurel extract and/or chlorophyll.

Because of the above-described composition, the filtrate of the lactic acid bacterial cultures have hair growth promoting as well as hair loss preventing effect. It is assumed that the components contained in the filtrate of the lactic acid 15 bacterial cultures have the effect of promoting blood circulation to the peripheral capillaries, and also that the components enhance the division and multiplication of the hair matrix cells and act as hair root activators by improving the lowered functions of the hair matrix cells. Particularly when 20 the lactic acid bacterium belonging to *Streptococcus* or *Lactobacillus* is used, various components produced by the lactic acid bacterium, which are present in the filtrate of the lactic acid bacterial culture and are supplied to the hair papilla, act synergistically and have the effect of promoting 25 the growth of the hair matrix cells.

In the present invention, "filtrate of culture" means the liquid fraction of the lactic acid bacterial culture, obtained by crushing the bacterial cells present in the culture medium (bacterial suspension) to make them into colloidal or dissolved form, and the removing the cellular residue. This filtrate can be separated by solid-liquid separation means like filtration, centrifuging, etc. In one embodiment of the present invention, the lactic acid bacteria used are those belonging to *Streptococcus* or *Lactobacillus*. However, in the hair growth tonic of the present invention, it is not limited to use the filtrate of the culture of the specified lactic acid bacteria. The hair growth tonic of the present invention can contain filtrates from cultures of any other lactic acid bacteria having a similar effect.

The hair growth tonic of the present invention can contain other known hair growth promoting components. Examples of such hair growth promoting components are activators of living cells such as laurel extract, and chlorophyll; blood circulation promoters and localized stimulants that promote blood flow to peripheral capillaries; nutrients (such as Vitamins and amino acids) for supplying nutrition to the area surrounding hair matrix cells; female hormone formulations that have antagonistic effect against male hormone; hair root activators for improving the lowered function of hair matrix cells; moisturizers for preventing scalp drying, etc.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the comparison of hair growth before the start of the test and the hair growth 4 or 5 months after treatment 5 with the filtrate of cultures of *Streptococcus lactis* culture from Example 1 (Formulation 2), applied to the scalp of three males (Top: Male A, Middle: Male B and Bottom: Male C) having alopecia.

10 BEST MODE FOR CARRYING OUT THE INVENTION

The hair growth tonic according to the present invention will be described in greater detail, referring to the Tables and the accompanying drawings.

“Lactic acid bacteria” is a general name for a group of 15 bacteria that obtain their energy by fermenting carbohydrates and produce large quantities of lactic acid. Lactic acid bacteria can be classified into cocci and bacilli. *Streptococcus*, *Leuconostoc*, *Pediococcus*, etc. belong to the group of cocci and *Lactobacillus*, *Vifidobacterium*, etc. belong 20 to the group of bacilli. The lactic acid bacteria in the present invention include any types of lactic acid bacteria belonging to the above-mentioned groups. Unnatural lactic acid bacteria such as recombinant lactic acid bacteria, variants of lactic acid bacteria obtained by artificially induced mutations, etc 25 are also included. The preferred lactic acid bacteria are those

which are not pathogens of humans and other animals. The commercially available lactic acid bacteria used for manufacturing foods such as fermented milk products, fermented meat products, fermented food, fermented soy bean milk, pickles, 5 etc. can be more preferably used. Such lactic acid bacteria are available from, for example, Chr. Hansen's Corp.

Examples of lactic acid bacteria that can be used in the present invention includes *Streptococcus* species such as *Streptococcus thermophilus*, *Streptococcus lactis*, and 10 *Streptococcus lactis* subsp. *Diacetylactis*; *Pediococcus* species such as *Pediococcus cerevisiae*, *Pediococcus acidilactici*, *Pediococcus penntosaceus*, *Pediococcus halophilus*, and *Pediococcus urinae-equii*; *Leuconostoc* species such as *Leuconostoc cremoris* and *Leuconostoc oenos*; 15 *Lactobacillus* species such as *Lactobacillus delbrueckii*, *Lactobacillus leuchmannii*, *Lactobacillus lactis*, *Lactobacillus bulgaricus*, *Lactobacillus helveticus*, *Lactobacillus fermentum*, *Lactobacillus brevis*, and *Lactobacillus viridescens*; *Bifidobacterium* species such as 20 *Bifidobacterium longum*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, and *Bifidobacterium infantis*.

Among these lactic acid bacteria, those belonging to the genus *Streptococcus* are gram-positive, non-sporulating and obligate to facultative anaerobic cocci of diameter 1 μm or less. 25 Normally, they are diplococci or streptococci. They are

negative for catalase and oxidase and produce dextrorotatory lactic acid in the homofermentation mode. Those belonging to the genus *Lactobacillus* are gram-positive, negative for catalase, and are obligate anaerobes to anaerobes. Normally 5 they are non-motile, do not produce spores, are bacilli, and aggregate into chains also. Both homofermentation and heterofermentation types are known to exist.

In one embodiment of the present invention, the filtrate of cultures of two of the lactic acid bacteria listed above, 10 *Streptococcus lactis* and *Lactobacillus bulgaricus*, are used. *Streptococcus lactis* belongs to cocci and *Lactobacillus bulgaricus* is a bacillus. Both are homofermentation type lactic acid bacteria. *Streptococcus lactis* is used as a starter in the production of dairy products such as fermented milk, 15 cheese, and butter. *Lactobacillus bulgaricus* is used as a starter for cheese and also widely used in the production of lactic acid drinks, yogurt, and the like.

The filtrate of the lactic acid bacterial culture used in the present invention can be obtained by culturing the 20 above-mentioned lactic acid bacteria, removing the solid components left after crushing the bacterial cells of the lactic acid bacteria in the culture medium obtained, i.e., the residue of the bacterial cells left after making the cell wall portion into a colloid or dissolving it.

25 The lactic acid bacterial culture can be produced under

any conditions, as long as they permit satisfactory multiplication of the lactic acid bacteria. The composition of culture medium, culturing temperature, culturing pH, culturing time, etc. may be varied, depending on the type of 5 the lactic acid bacteria used. The culturing conditions and culturing method, for instance, can be selected from those given in Bergey's Manual of Determinative Bacteriology (8th Edition, 1974) and those given in the user's manuals provided by the manufacturers of commercially available lactic acid bacteria.

10 The medium can be prepared, for example, by combining one or more carbon sources and nitrogen sources such as whey glucose, and peptone. The culturing temperature can be varied, depending on the type of bacterium used. The normally used culturing temperature (approx. 20-45°C) is suitable. The 15 culturing can be done at an even higher temperature in the case of heat-resistant lactic acid bacteria. The bacteria grow quite well in the pH range 2-4. However, the culturing pH of the initial medium may be neutral or weakly alkaline.

The culturing may be done for a period of a few hours to 20 72 hours, preferably for about 15-50 hours. The amount of lactic acid bacterium culture to be added per liter of the medium is 10-100 ml.

A set of the culturing conditions is given below, as an example. But this in no way limits the scope of the invention.

25 When the lactic acid bacteria belonging to the genus

Streptococcus are used, the culturing can be done in the MRS medium (available from Difco, Co.) at 30-37°C and pH 6.8, for 24-48 hours. In the case of the lactic acid bacteria belonging to the genus Leuconostoc also, culturing can be done in the MRS medium at 30-37°C, and pH 6.8, for 24-48 hours. For the lactic acid bacteria belonging to the genus Pediococcus also, culturing can be done in the MRS medium at 30-37°C and pH 6.8, for 24-48 hours.

10 In the case of the lactic acid bacteria belonging to the genus Lactobacillus also, culturing can be done in the MRS medium at 30-37°C and pH 6.8, for 24-48 hours.

15 For the lactic acid bacteria belonging to the genus Bifidobacterium, the culturing may be done in BL or EG medium under anaerobic conditions at 30-37°C and pH 7-8, for 24-48 hours.

20 In a specific example of the present invention, a medium containing whey and glucose (10% and 2%, respectively, for example) is inoculated with a lactic acid bacterium, and stationary culturing is done at 35-37°C for 48 hours.

25 After culturing the lactic acid bacteria, the bacterial cells are crushed, the culture suspension is filtered or centrifuged to remove the residue of bacterial cells, and the filtrate of cultures is recovered.

25 The compositions of the media described above are given below.

MRS medium (for 1 liter of medium)

| | | |
|----|---------------------------------------|--------|
| | Peptone (Oxoid) | 10 g |
| | Meat extract | 10 g |
| | Yeast extract | 5 g |
| 5 | K ₂ HPO ₄ | 2 g |
| | Diammonium hydrogen citrate | 2 g |
| | Glucose | 20 g |
| | Tween 80 | 1 g |
| | Sodium acetate | 5 g |
| 10 | MgSO ₄ · 7H ₂ O | 0.58 g |
| | MnSO ₄ · 4H ₂ O | 0.28 g |

(The volume was made up to 1 liter with purified water, pH 6.2-6.6, sterilized for 15 minutes at 121°C)

BL (Agar) medium

| | | |
|----|--------------------------------|--------|
| 15 | Beef extract (Oxoid) | 3 g |
| | Proteose peptone No. 3 (Difco) | 10 g |
| | Trypticase (BBL) | 5 g |
| | Phytone (BBL) | 3 g |
| | Yeast extract (Difco) | 5 g |
| 20 | Liver extract | 150 ml |
| | Glucose | 10 g |
| | Soluble starch | 0.5 g |
| | Solution A | 10 ml |
| | Solution B | 5 ml |
| 25 | Tween 80 | 1 g |

| | |
|--|--------|
| Bactoagar (Difco) | 15 g |
| L-Cysteine hydrochloride (5% solution) | 10 ml |
| Horse blood | 50 ml |
| Purified water | 765 ml |
| 5 pH 7.2 | |

Solution A: 25 g of K_2HPO_4 and 25 g of K_2HPO_4 are dissolved in 250 ml of distilled water.

Solution B: 10 g of $MgSO_4 \cdot 7H_2O$, 0.5 g of $FeSO_4 \cdot 7H_2O$, 0.5 g of NaCl, and 0.337 g of $MnSO_4$ are dissolved in 250 ml of purified 10 water.

Liver extract: 10 g of liver powder (Kyokuto) is extracted for about one hour in 170 ml of purified water placed in a 50-60°C warm water bath. It is heated for several minutes at 100°C and filtered through filter paper after adjusting the pH thereof 15 to 7.2.

Preparation of medium: The components other than the L-cysteine hydrochloride and horse blood are heated to dissolve them. Then, after adjusting the pH, the solution is sterilized for 20 minutes at 115°C. The solution is then cooled to 50°C, 20 the cysteine hydrochloride and horse blood are added to prepare flats.

EG (EUGON) medium

| | |
|--------------------------|-------|
| Bactotryptose (Difco) | 1.5% |
| Bactosoeton (Difco) | 0.5% |
| 25 Bactodextrose (Difco) | 0.55% |

| | |
|---------------------------------|-------|
| L-Cysteine (Difco) | 0.07% |
| NaCl | 0.4% |
| Na ₂ SO ₃ | 0.02% |
| Purified water to make | 100% |

5 The hair growth tonic of the present invention contains the filtrate of a lactic acid bacterial culture thus obtained as its active component. The amount of the filtrate of cultures in the composition is as much as would give a suitable effect on hair growth, and is not particularly limited. It can, for 10 example, be 0.1% or more, preferably 0.1-20% (% by volume in all cases). The filtrate of the lactic acid bacterial culture of the present invention can be concentrated to a suitable level, such as 2-10 times, preferably 3-5 times, by employing an ordinary method of concentration, before adding to the hair 15 growth tonic as the active ingredient.

 Lactic acid bacteria are known to synthesize vitamins of the B group inside human guts, activate leukocytes, enhance the bacterial infection preventing activity by strengthening the immune system, and produce antibacterial substances that 20 exclude harmful bacteria. They are also known to adsorb carcinogens and enable their excretion through human stools, and to have a blood cholesterol lowering effect. Through the present invention, it has now become clear that the filtrate of cultures thereof have hair growth promoting and hair loss 25 prevention effect. Some components contained in the filtrates

of lactic acid bacterial cultures have the effect of promoting blood flow to the terminal capillaries, promoting of the division and multiplication of hair matrix cells, and activation of hair roots which improves the lowered functions 5 of the hair matrix cells. Which components are effective is not very clear. However, it is assumed that various components produced by lactic acid bacteria, which are present in the filtrate of lactic acid bacterial cultures, act synergistically when supplied to the hair papilla and exert a hair growth 10 promoting effect on the hair matrix cells.

In the hair growth tonic of the present invention, the above-described culture filtrate can be used singly. However, for the sake of ease in use, it is preferable to use it along with carriers such as excipients and diluents permitted in drugs 15 (including quasi drugs, used with this meaning hereinafter) and cosmetics. Examples of such carriers include purified water, ordinary water, physiological saline, ethanol, etc., all of which are normally used in hair growth tonics.

The hair growth tonic of the present invention can contain 20 other known hair growth promoting components. Examples of such components include activators of living cells (for example laurel extract, chlorophyll, etc.); blood flow promoters (such as alder fly extract, cephalanthin, Vitamin E and its derivatives, γ -orizanol, etc) and local stimulants (such as 25 capsicum tincture, ginger tincture, cantharis tincture, benzyl

ester of nicotinic acid, etc) that promote blood flow to the peripheral capillaries; nutrient preparation that supply nutrients (for example, Vitamins A, B₁, B₂, B₆, E and their derivatives, pantothenic acid and its derivatives, vitamins 5 such as biotin, amino acids such as cystine, cysteine, methionine, leucine, tryptophan, amino acid extracts) to the area surrounding the hair matrix cells; female hormones (for example, estradiol, ethynodiol, etc) which have antagonistic action against the male hormone; hair root 10 activators (such as pantothenic acid and its derivatives, placenta extract, allantoin, Kanko-so No. 301, etc) for improving the lowered function of the hair matrix cells; moisturizers (such as glycerol and pyrrolidone carboxylic acids) to prevent drying of the scalp, etc.

15 The hair growth tonic of the present invention can also contain drugs for preventing dandruff and itchiness. Examples of such drugs include keratin exfoliant-resolvents such as salicylic acid, sulfur, resorcinol, and selenium sulfide; anti-seborrhea agents such as pyridoxine and its derivatives; 20 disinfectants such as pyrethion zinc, trichlorocarbanilide/acetic acid tocophenol, benzalkonium chloride, benzethonium chloride, chlorohexidine, and hinoki (Japanese cypress) thiol; antiinflammatory agents such as glycyrrhetic acid and its derivatives, hydrocortisone acetate, 25 and prednisolone; antipruritic agent such as diphenhydramine

hydrochloride, maleic acid chlorophenylamine, camphor, and dl- or l-menthol. In addition to these, it can contain suitable amounts of components described in *Keshohin Betsu Kyokakijun* (Permissible Standards for Cosmetics) (Yakuji Nopposha) such 5 as perfumes, fresheners, emulsifiers, solubilizing agents, pH regulators, and coloring agents.

The hair growth tonic of the present invention can be used as a drug as well as a cosmetic. Its effects as a drug are the improvement and prevention of circular alopecia areata, 10 premature alopecia, and male pattern alopecia. It is also effective in promoting hair revival, hair regeneration, hair growth, and hair nourishment, and in preventing falling of hair. Because of this, the hair growth tonic of the present invention can be used effectively as a cosmetic. The lactic acid bacteria 15 used in the present invention are used in the preparation of food or are naturally present in food. Thus, the bacterial culture medium has a very low toxicity.

The hair growth tonic may be in the form of a liquid formulation, emulsion, cream, lotion, gel, liquid, foam, spray, 20 etc. It can also be compounded with shampoos, rinses, and treatments. For example, oil and fats (such as olive oil, and triglyceride), hydrocarbons (such as liquid paraffin, vaseline, and yellow beeswax), higher fatty acids, higher fatty acid esters, higher alcohols, surfactants, tackifiers, chelating 25 agents, and the like may be used to prepare a cream. To prepare

a gel, water soluble polymers (such as carboxyvinyl polymer, and methyl cellulose), setting agents (such as polyvinylpyrrolidone), alkalies, surfactants, chelating agents, and the like may be used. If it is in the form of a 5 spray or foam, atomizing agents (such as dimethyl ether, and liquefied petroleum gas) may be used. Gums (such as gum tragacanth, and gum karaya), polymers (such as polyvinylpyrrolidone/vinyl acetate copolymer), and the like may be used in the case of lotions.

10 The hair growth tonic of the present invention may be applied (for example, by spraying 1 ml) on the scalp at least once a day, preferably twice or more often, and the scalp may be stimulated by tapping or massaging to achieve a significant hair growth promoting effect.

15 The hair growth tonic of the present invention will now be explained in greater detail referring to some examples. However, the scope of the invention is not limited by these examples.

20 [Example 1] Preparation of hair growth tonic containing filtrate of a *Streptococcus lactis* culture

A medium prepared by adding 10% of whey and 2% of glucose to 1 liter of sterilized water was inoculated with 50 ml of *Streptococcus lactis*. It was then subjected to stationary culture for 48 hours at 35°C. After culturing, the cell walls 25 were crushed, made into a colloid and dissolved. This bacterial

suspension was centrifuged to remove the bacterial cell residues. The culture filtrate thus obtained was used in the preparation of the following examples of the hair growth tonic (the quantities are expressed in % by volume).

5 Formulation 1

| | | |
|--|--|------|
| | Filtrate of Streptococcus lactis culture | 1.5% |
| | Pure water to make up | 100% |

Formulation 2

| | | |
|----|--|------|
| | Filtrate of Streptococcus lactis culture | 1.5% |
| 10 | Laurel extract | 0.5% |
| | Ethanol | 15% |
| | Pure water to make up | 100% |

Formulation 3

| | | |
|----|--|------|
| | Filtrate of Streptococcus lactis culture | 1.5% |
| 15 | Capsicum tincture | 0.1% |
| | dl-Menthol | 0.1% |
| | Water-soluble placenta extract | 0.1% |
| | Laurel extract | 0.5% |
| | Ethanol | 15% |
| 20 | Pure water to make up | 100% |

[Example 2] Preparation of hair growth tonic containing filtrate of Lactobacillus bulgaricus culture

A medium prepared by adding 10% of whey and 2% of glucose to 1 liter of sterilized water was inoculated with 50 ml of 25 Lactobacillus bulgaricus. It was then subjected to stationary

culture for 48 hours at 35°C. After culturing, the cell walls were crushed, made into a colloid and dissolved. This bacterial suspension was centrifuged to remove the bacterial cell residues. The culture filtrate thus obtained was used in the 5 preparation of the following examples of the hair growth tonic (the quantities are expressed in % by volume).

Formulation 4

| | | |
|--|--|------|
| | Filtrate of Lactobacillus bulgaricus culture | 1.5% |
| | Purified water to make up | 100% |

10 Formulation 5

| | | |
|--|--|------|
| | Filtrate of Lactobacillus bulgaricus culture | 1.5% |
| | Laurel extract | 0.5% |
| | Ethanol | 15% |
| | Purified water to make up | 100% |

15 Formulation 6

| | | |
|----|--|------|
| | Filtrate of Lactobacillus bulgaricus culture | 1.5% |
| | Capsicum tincture | 0.1% |
| | dl-Menthol | 0.1% |
| | Water-soluble placenta extract | 0.1% |
| 20 | Laurel extract | 0.5% |
| | Ethanol | 15% |
| | Purified water to make | 100% |

[Example 3] Hair growth test and results

A suitable amount of the hair growth tonic of Example 1 25 (Formulation 2) was applied twice a day, morning and evening,

on the scalp of three alopecic males. The effect of 4 or 5 months of treatment was evaluated visually. Significant effect on hair growth occurred in all the cases (refer to Fig. 1). Similar positive effect on hair growth was confirmed with the hair growth tonic of Example 2 (Formulation 5) when applied on three alopecic men, for 2-3 months. The results are shown in Table 1 (for Formulation 2) and Table 2 (for Formulation 5).

[Table 1]

| | | <u>Test subject</u> | <u>Sex & Age</u> | <u>Duration of use</u> | <u>Effect</u> |
|----|---|---------------------|----------------------|------------------------|---------------|
| 10 | A | | Male, in his 40's | 4 months | ++ |
| | B | | Male, in his 40's | 5 months | +++ |
| | C | | Male, in his 40's | 5 months | ++ |

[Table 2]

| | | <u>Test subject</u> | <u>Sex & Age</u> | <u>Duration of use</u> | <u>Effect</u> |
|----|---|---------------------|----------------------|------------------------|---------------|
| 15 | D | | Male, in his 50's | 3 months | ++ |
| | E | | Male, in his 50's | 3 months | ++ |
| | F | | Male, in his 60's | 2 months | + |

20 Meaning of symbols

- : Worsened

0 : No visible effect

+ : No visible effect, but positive effect could be confirmed by microscopic observation

25 ++ : Effect was visible

+++ : Very significant effect could be seen

The above examples show that the hair growth tonic of the present invention is effectively used in prevention of hair loss and its treatment.

5 [Example 4] Preparation of hair growth tonic and hair growth test

A hair growth tonic having the composition shown below was prepared using the Streptococcus lactis culture filtrate prepared in Example 1. The tonic was applied on three males.

10 The duration of usage thereof and the results obtained are given below under (1)-(3).

Formulation 7

| | |
|----------------------------------|------|
| Filtrate of Streptococcus lactis | 2% |
| Purified water to make up | 100% |

15 (1) Male I (50 years old)

The subject was bald on the back of his head. This baldness was so extensive that even the hair whirl at the top of the head could not be seen. Starting from October 1999 about 5 cc of the hair growth tonic prepared according to the 20 Formulation 7 was sprayed daily on the back of his head, for about 3 months. His hair growth recovered almost to the level of the surrounding area.

(2) Male G (65 years old)

His head was as bald as an egg. When about 5 cc of the 25 above-mentioned hair growth tonic was applied daily, for about

2 years starting from January 1998, hair growth recovered to the level of a close cropped head of hair.

(3) Male K (60 years old)

He was not bald. When about 3 cc of the tonic was applied 5 daily for 10 days starting from January 10, 2000, the falling of hair and dandruff disappeared.

INDUSTRIAL APPLICABILITY

As discussed above, the hair growth tonic according to 10 the present invention effectively promotes hair growth. It is useful as a drug and cosmetic that can prevent hair loss.

CLAIMS

1. A hair growth tonic containing a filtrate of lactic acid bacterial culture as an active ingredient.
2. The hair growth tonic according to claim 1, 5 characterized in that the lactic acid bacterium is a bacterium belonging to Streptococcus or Lactobacillus.
3. The hair growth tonic according to claim 2, characterized in that the lactic acid bacterium of Streptococcus is Streptococcus lactis.
- 10 4. The hair growth tonic according to claim 2, characterized in that the lactic acid bacterium of Lactobacillus is Lactobacillus bulgaricus.
5. The hair growth tonic according to claim 2, characterized by further comprising other components known to 15 promote hair growth.
6. The hair growth tonic according to claim 5, characterized in that the other components known to promote hair growth are laurel extract and/or chlorophyll.


ABSTRACT

A hair growth tonic contains, as an active ingredient, a filtrate of lactic acid bacterial culture such as 5 *Streptococcus lactis*, and *Lactobacillus bulgaricus*. The use of this type of hair growth tonic promotes hair regeneration, hair growth and hair nourishment.

09/743704

1 / 1

Fig. 1



Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HAIR GROWTH STIMULANTS

the specification of which (check one)

[] is attached hereto;
 [] was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appln. No. _____ *; or
 [x] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/JP00/03017 filed May 11, 2000, entry requested on _____ *; national stage application received U.S. Appln. No. _____ *; §371/§102(e) date _____ * (* if known)

and was amended on _____ (if applicable).
(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 and 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

| | | | | |
|------------------------------|---------------------------|---|---|-----------------------------|
| <u>11-134132</u> (Number) | <u>Japan</u> (Country) | <u>14/05/1999</u> (Day Month Year Filed) | <input checked="" type="checkbox"/> YES | <input type="checkbox"/> NO |
| (Number) | (Country) | (Day Month Year Filed) | <input type="checkbox"/> YES | <input type="checkbox"/> NO |

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or prior PCT application(s) designating the U.S. listed below, or under §119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

| | | |
|-------------------|------------------------|--|
| (Application No.) | (Day Month Year Filed) | (Status: patented, pending, abandoned) |
| (Application No.) | (Day Month Year Filed) | (Status: patented, pending, abandoned) |
| (Application No.) | (Day Month Year Filed) | (Status: patented, pending, abandoned) |

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444; i.e.,

BROWDY AND NEIMARK, P.L.C.

624 Ninth Street, N.W.

Washington, D.C. 20001-5303

(202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from KANESAKA & SAKAI as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

Title: _____
 U.S. Application filed _____, Serial No. _____
 PCT Application filed _____, Serial No. _____

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

| | | | |
|---|--|--|--------------------|
| FULL NAME OF FIRST INVENTOR <u>Isao Horiuchi</u> | | INVENTOR'S SIGNATURE <i>Isao Horiuchi</i> | DATE 24/12/2000 |
| RESIDENT 1014-banchi, Ichinomiya, Ichinomiya-cho, Higashi-Yatsushiro-ku, Yamanashi-ken, 405-0056 JAPAN | | CITIZENSHIP JAPANESE <i>JPX</i> | |
| POST OFFICE ADDRESS As above | | | |
| FULL NAME OF SECOND JOINT INVENTOR | | INVENTOR'S SIGNATURE | DATE |
| RESIDENT | | CITIZENSHIP | |
| POST OFFICE ADDRESS | | | |
| FULL NAME OF THIRD JOINT INVENTOR | | INVENTOR'S SIGNATURE | DATE |
| RESIDENT | | CITIZENSHIP | |
| POST OFFICE ADDRESS | | | |
| FULL NAME OF FOURTH JOINT INVENTOR | | INVENTOR'S SIGNATURE | DATE |
| RESIDENT | | CITIZENSHIP | |
| POST OFFICE ADDRESS | | | |
| FULL NAME OF FIFTH JOINT INVENTOR | | INVENTOR'S SIGNATURE | DATE |
| RESIDENT | | CITIZENSHIP | |
| POST OFFICE ADDRESS | | | |
| FULL NAME OF SIXTH JOINT INVENTOR | | INVENTOR'S SIGNATURE | DATE |
| RESIDENT | | CITIZENSHIP | |
| POST OFFICE ADDRESS | | | |
| FULL NAME OF SEVENTH JOINT INVENTOR | | INVENTOR'S SIGNATURE | DATE |
| RESIDENT | | CITIZENSHIP | |
| POST OFFICE ADDRESS | | | |